SCHEMBL6977578

SCHEMBL6977578

O=C(NCC1(c2nc(-c3ccccc3)cs2)CCOCC1)c1cccc(-c2noc(C(=O)C(F)(F)F)n2)c1

nearest known ligand 0.80

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HDAC4 P56524 5/20 0.80
HDAC8 Q9BY41 5/20 0.80
HDAC7 Q8WUI4 4/20 0.80
HDAC9 Q9UKV0 4/20 0.80
HDAC5 Q9UQL6 4/20 0.80
HDAC6 Q9UBN7 4/20 0.80
HDAC1 Q13547 3/20 0.80
HDAC3 O15379 2/20 0.80
HDAC2 Q92769 1/20 0.80
HDAC10 Q969S8 1/20 0.80
HDAC11 Q96DB2 1/20 0.80
KCNH2 Q12809 1/20 0.54
ALDH1A1 P00352 3/20 0.39
L3MBTL1 Q9Y468 1/20 0.37
HTT P42858 1/20 0.37
GAA P10253 1/20 0.36
NR1H4 Q96RI1 1/20 0.35
P2RX7 Q99572 2/20 0.34
KCNA3 P22001 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14752553 0.90 HDAC4 (0.76) HDAC4HDAC8HDAC7HDAC9HDAC5
SCHEMBL25455687 0.89 HDAC4 (0.88) HDAC4HDAC8HDAC7HDAC9HDAC5
SCHEMBL29349803 0.89 HDAC4 (1.00) HDAC4HDAC8HDAC7HDAC9HDAC5
SCHEMBL6976560 0.89 HDAC4 (1.00) HDAC4HDAC8HDAC7HDAC9HDAC5
SCHEMBL14752305 0.86 HDAC4 (0.78) HDAC4HDAC8HDAC7HDAC9HDAC5
SCHEMBL6974372 0.86 HDAC4 (0.78) HDAC4HDAC8HDAC7HDAC9HDAC5
SCHEMBL2224717 0.86 HDAC4 (0.71) HDAC4HDAC8HDAC7HDAC9HDAC5
SCHEMBL2228775 0.86 HDAC4 (0.77) HDAC4HDAC8HDAC7HDAC9HDAC5
SCHEMBL6978228 0.85 HDAC6 (0.69) HDAC4HDAC8HDAC7HDAC9HDAC5
SCHEMBL6974340 0.85 HDAC6 (0.76) HDAC4HDAC8HDAC7HDAC9HDAC5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2533783-B1 COMPOUNDS AND METHODS for the inhibition of HDAC TEMPERO PHARMACEUTICALS INC (US) 2015-11-04 EP claimed
US-20130059883-A1 COMPOUNDS AND METHODS TEMPERO PHARMACEUTICALS, INC. 2013-03-07 US claimed
WO-2013009810-A1 METHODS OF TREATMENT TEMPERO PHARMACEUTICALS, INC. (US) 2013-01-17 WO claimed
WO-2013009830-A1 METHODS OF TREATMENT TEMPERO PHARMACEUTICALS, INC. (US) 2013-01-17 WO claimed
EP-2533783-B1 COMPOUNDS AND METHODS for the inhibition of HDAC TEMPERO PHARMACEUTICALS INC (US) 2015-11-04 EP disclosed
EP-2533783-B1 COMPOUNDS AND METHODS for the inhibition of HDAC TEMPERO PHARMACEUTICALS INC (US) 2015-11-04 EP disclosed
US-20150038534-A1 COMPOUNDS AND METHODS TEMPERO PHARMACEUTICALS, INC. 2015-02-05 US disclosed
US-20150038534-A1 COMPOUNDS AND METHODS TEMPERO PHARMACEUTICALS, INC. 2015-02-05 US disclosed
US-20150038534-A1 COMPOUNDS AND METHODS TEMPERO PHARMACEUTICALS, INC. 2015-02-05 US disclosed
US-8901156-B2 Compounds and methods TEMPERO PHARMACEUTICALS, INC. (US) 2014-12-02 US disclosed
US-8901156-B2 Compounds and methods TEMPERO PHARMACEUTICALS, INC. (US) 2014-12-02 US disclosed
US-8901156-B2 Compounds and methods TEMPERO PHARMACEUTICALS, INC. (US) 2014-12-02 US disclosed
US-20130059883-A1 COMPOUNDS AND METHODS TEMPERO PHARMACEUTICALS, INC. 2013-03-07 US disclosed
US-20130059883-A1 COMPOUNDS AND METHODS TEMPERO PHARMACEUTICALS, INC. 2013-03-07 US disclosed
US-20130059883-A1 COMPOUNDS AND METHODS TEMPERO PHARMACEUTICALS, INC. 2013-03-07 US disclosed
WO-2011088181-A9 COMPOUNDS AND METHODS TEMPERO PHARMACEUTICALS, INC. (US) 2013-01-31 WO disclosed
WO-2013009810-A1 METHODS OF TREATMENT TEMPERO PHARMACEUTICALS, INC. (US) 2013-01-17 WO disclosed
WO-2013009830-A1 METHODS OF TREATMENT TEMPERO PHARMACEUTICALS, INC. (US) 2013-01-17 WO disclosed
WO-2011088181-A1 COMPOUNDS AND METHODS TEMPERO PHARMACEUTICALS, INC. (US) 2011-07-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150038534-A1 COMPOUNDS AND METHODS XDH, LPXN, CCNY HDAC4 1441/4885HDAC8 1583/4885HDAC7 1956/4885
US-20130059883-A1 COMPOUNDS AND METHODS XDH, LPXN, CCNY HDAC4 1441/4885HDAC8 1583/4885HDAC7 1956/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.